MedPath

DS BIOPHARMA LIMITED

🇮🇪Ireland
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

9

Active:3
Completed:5

Trial Phases

2 Phases

Phase 1:4
Phase 2:5

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (9 trials with phase data)• Click on a phase to view related trials

Phase 2
5 (55.6%)
Phase 1
4 (44.4%)

Efficacy and Safety of Orally Administered DS107 in Adult Patients With Moderate to Severe Atopic Dermatitis

Phase 2
Terminated
Conditions
Atopic Dermatitis
Interventions
Drug: Placebo
First Posted Date
2019-01-25
Last Posted Date
2022-11-28
Lead Sponsor
DS Biopharma
Target Recruit Count
219
Registration Number
NCT03817190
Locations
🇺🇸

DS Investigational Site 524, Birmingham, Alabama, United States

🇺🇸

DS Investigational Site 528, Huntington Beach, California, United States

🇺🇸

DS Investigational Site 502, Los Angeles, California, United States

and more 47 locations

Efficacy and Steroid Sparing Potential Study of DGLA Cream in Early Childhood Patients With Moderate to Severe Atopic Dermatitis

Phase 2
Completed
Conditions
Atopic Dermatitis
Interventions
First Posted Date
2018-09-19
Last Posted Date
2019-02-08
Lead Sponsor
DS Biopharma
Target Recruit Count
5
Registration Number
NCT03676933
Locations
🇮🇪

DS Biopharma Investigational Site, Dublin, Ireland

Efficacy and Steroid Sparing Potential Study of DGLA Cream in Patients With Moderate to Severe Atopic Dermatitis

Phase 2
Completed
Conditions
Atopic Dermatitis
Interventions
Drug: Vehicle
First Posted Date
2018-09-18
Last Posted Date
2018-09-18
Lead Sponsor
DS Biopharma
Target Recruit Count
42
Registration Number
NCT03676036
Locations
🇩🇪

DS Biopharma Investigational Site, Lubeck, Germany

Safety and Efficacy Study of Topically Applied DS107 Cream in Mild to Moderate Atopic Dermatitis Patients (AD)

Phase 2
Completed
Conditions
Atopic Dermatitis
Interventions
Other: Vehicle cream
First Posted Date
2016-10-06
Last Posted Date
2022-11-22
Lead Sponsor
DS Biopharma
Target Recruit Count
327
Registration Number
NCT02925793
Locations
🇿🇦

DS Biopharma Site, Cape Town, South Africa

Efficacy and Safety Study of Orally Administered DS107 in Moderate to Severe Atopic Dermatitis Patients

Phase 2
Completed
Conditions
Atopic Dermatitis
Interventions
Drug: Placebo
First Posted Date
2016-08-12
Last Posted Date
2022-10-10
Lead Sponsor
DS Biopharma
Target Recruit Count
321
Registration Number
NCT02864498
Locations
🇿🇦

DS Biopharma Site, Cape Town, South Africa

  • Prev
  • 1
  • 2
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.